Protagonist Therapeutics (PTGX) Selects Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/27/2022
- Wall Street rallies, snaps longest weekly losing streak in decades
- 'Always Bet on Michael': Dell (DELL) Stock Soars After Crushing Estimates, Analysts Say Results are Impressive
- Credit Suisse Says Tesla (TSLA) Stock Offers an Attractive Entry Point, Sees Nearly 60% Upside From Here
- Citi Downgrades US Equities to Neutral on Recession Risk
- Elon Musk Says Recession Could Last 12 to 18 Months, But 'Actually a Good Thing'
- Wells Fargo (WFC) has fired dozens of loan officers accused of misusing appraisal waivers. Some say the bank gave them mixed signals - Business Insider
- Broadcom (AVGO) to Acquire VMware (VMW) for Approximately $61 Billion in Cash and Stock
- Wall Street jumps on retailer outlook hikes, ebbing Fed fears
- Kohl's (KSS) Ticks Lower as Another Bidder Losing Interest
- 'His Personality Suggests Resolution Depends on Him Alone': Jefferies Discusses Elon Musk, Cuts PT on Tesla (TSLA) on Increased Risk Profile
- Pre-Open Stock Movers 05/27: Dell, Ulta Surge on Earnings Beats; Gap Plunges (more...)
- After-Hours Stock Movers 05/26: Ulta, Dell Jump on Earnings; Gap, American Eagle Sink (more...)
- Pre-Open Stock Movers 05/26: Retailers Dollar Tree, Macy's, and Williams-Sonoma Jump on Results; Nutanix, Snowflake, NVIDIA Fall (more...)
- After-Hours Stock Movers 05/25: NVIDIA, Snowflake Sink on Weaker Guidance; Williams-Sonoma Surges on Strong Numbers (more...)
- Pre-Open Stock Movers 05/25: Retailers Express, Nordstrom Gain Following Earnings; Verrica Pharma Sinks on FDA CRL (more...)
Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications
December 2, 2021 4:05 PM ESTNEWARK, Calif., Dec. 2, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the selection of PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 (IL-23) pathway, under the Company's collaboration with Janssen Biotech, Inc. (Janssen). In addition to the previously announced Phase 2 clinical study of PN-235 in psoriasis, new Phase 2 clinical studies of PN-235 in inflammatory bowel diseases (IBD) are expected to commence in late 2022. Further development of PN-232 (JNJ-7510586) will be discontinued in favor of PN-235 based on its... More
